Interleukin-13 in asthma and chronic obstructive pulmonary disease:from pathogenesis to targeted therapy
LI Zishuo
XU Xia
Abstract：Chronic respiratory diseases(CRDs),primarily bronchial asthma and chronic obstructive pulmonary disease(COPD),are characterized by chronic airway inflammation and remodeling.Their high morbidity and mortality rates present major challenges to global health.Interleukin-13(IL-13),a central mediator of the type 2 immunity,activate the JAK-STAT6 signaling pathway via the IL-4Rα/IL-13Rα1 receptor complex,or regulate in tumors and fibrotic diseases through IL-13Rα2.In the pathogenesis of asthma and COPD,IL-13 promotes pathological changes-including mucus hypersecretion,goblet cell hyperplasia,airway smooth muscle abnormalities,and epithelial barrier disruption via the JAK-STAT6 pathway.This review examines current states and future prospects of therapeutic strategies targeting IL-13,such as monoclonal antibodies and cell therapies,aiming to provide knowledge for targeted therapy.
Keywords：interleukin-13asthmachronic obstructive pulmonary disease(COPD)pathogenesistargeted therapy
Publication Date：2026-02-28
Online Publishing Date：2026-01-28(First online date of this platform, not the publication date of the document)
Pages：12( 37-48 )